Vaccine maker Adimmune Corp (國光生技) has gained an approval from Indonesia’s health regulator to conduct phase 1 and 2 clinical trials for its experimental COVID-19 vaccine in the Southeast Asian country, as it aims to tap the Muslim-based market with halal certification, the company said yesterday.
The trials in Indonesia would be Adimmune’s first overseas human tests for its experimental COVID-19 vaccine, after the Ministry of Health and Welfare ordered it to redo its phase 1 trial in Taiwan in December last year to determine the optimal dosage.
Adimmune yesterday said that the Indonesian trials would determine the optimal dosage for its vaccine to generate adequate protection against COVID-19 variants and prove its efficacy.
Photo courtesy of Adimmune Corp
The company plans to recruit 240 healthy adults aged between 18 and 65 to participate in the phase 2 trials, spokesman Pan Fei (潘飛) told the Taipei Times yesterday.
Despite encountering a setback in Taiwan, Adimmune did not modify the formula of its COVID-19 vaccine, dubbed AdimrSC-2f, nor its recombinant protein manufacturing technology, Pan said.
Adimmune’s candidate was developed in spring last year, before the emergence of the SARS-CoV-2 Delta variant. However, the company said it had tested its candidate against the variant in animal tests earlier this year, and that it showed good potential.
Unlike most finished clinical trials, which provide participants with two doses of an experimental vaccine, Adimmune’s clinical trials in Indonesia would give participants three doses, Pan said, adding that the company’s phase 2 trial would require more time and results are expected to be released next year.
The company is to produce the experimental COVID-19 vaccine at its factory in Taiwan and export it to Indonesia for the human trials, in collaboration with the Faculty of Medicine and Health Sciences at Universitas Gadjah Mada, Pan said.
Adimmune said it expects to complete the phase 1 and 2 trials early next year, but it would not seek emergency use authorization (EUA) upon completion, Pan said.
Instead, the company plans to apply to the Indonesian regulator to conduct a phase 3 trial there, he said.
“Timing for applying for an EUA has passed, as there are many available COVID-19 vaccines on the market,” Pan said. “Besides, an EUA is temporary. We aim to conduct the clinical trials without missing any steps and apply for a marketing approval that is valid for a long time.”
If Adimmune gains marketing approval from Indonesia for its COVID-19 vaccines, there is a good chance that the company would be able to provide its vaccine to other Muslim markets, Pan said, adding that the company has obtained a halal certification with its COVID-19 vaccine candidate.
Indonesia has the world’s largest Muslim population, consisting of about 87 percent of its 270.6 million inhabitants.
As with Moderna Inc, Adimmune would consider combining its flu vaccine into COVID-19 vaccine if its candidate is approved, although that mixture would not be a focus for research and development at this time, Pan said.
SEMICONDUCTOR SERVICES: A company executive said that Taiwanese firms must think about how to participate in global supply chains and lift their competitiveness Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) yesterday said it expects to launch its first multifunctional service center in Pingtung County in the middle of 2027, in a bid to foster a resilient high-tech facility construction ecosystem. TSMC broached the idea of creating a center two or three years ago when it started building new manufacturing capacity in the US and Japan, the company said. The center, dubbed an “ecosystem park,” would assist local manufacturing facility construction partners to upgrade their capabilities and secure more deals from other global chipmakers such as Intel Corp, Micron Technology Inc and Infineon Technologies AG, TSMC said. It
NO BREAKTHROUGH? More substantial ‘deliverables,’ such as tariff reductions, would likely be saved for a meeting between Trump and Xi later this year, a trade expert said China launched two probes targeting the US semiconductor sector on Saturday ahead of talks between the two nations in Spain this week on trade, national security and the ownership of social media platform TikTok. China’s Ministry of Commerce announced an anti-dumping investigation into certain analog integrated circuits (ICs) imported from the US. The investigation is to target some commodity interface ICs and gate driver ICs, which are commonly made by US companies such as Texas Instruments Inc and ON Semiconductor Corp. The ministry also announced an anti-discrimination probe into US measures against China’s chip sector. US measures such as export curbs and tariffs
The US on Friday penalized two Chinese firms that acquired US chipmaking equipment for China’s top chipmaker, Semiconductor Manufacturing International Corp (SMIC, 中芯國際), including them among 32 entities that were added to the US Department of Commerce’s restricted trade list, a US government posting showed. Twenty-three of the 32 are in China. GMC Semiconductor Technology (Wuxi) Co (吉姆西半導體科技) and Jicun Semiconductor Technology (Shanghai) Co (吉存半導體科技) were placed on the list, formally known as the Entity List, for acquiring equipment for SMIC Northern Integrated Circuit Manufacturing (Beijing) Corp (中芯北方積體電路) and Semiconductor Manufacturing International (Beijing) Corp (中芯北京), the US Federal Register posting said. The
India’s ban of online money-based games could drive addicts to unregulated apps and offshore platforms that pose new financial and social risks, fantasy-sports gaming experts say. Indian Prime Minister Narendra Modi’s government banned real-money online games late last month, citing financial losses and addiction, leading to a shutdown of many apps offering paid fantasy cricket, rummy and poker games. “Many will move to offshore platforms, because of the addictive nature — they will find alternate means to get that dopamine hit,” said Viren Hemrajani, a Mumbai-based fantasy cricket analyst. “It [also] leads to fraud and scams, because everything is now
RSS